| Literature DB >> 33193082 |
Michele Campaigne Larsen1, Jinwoo Lee1,2, Joan S Jorgensen2,3, Colin R Jefcoate1,2.
Abstract
Entities:
Keywords: CRTC2; SIK1; START proteins; cholesterol trafficking; nascent HDL formation; sm-FISH
Year: 2020 PMID: 33193082 PMCID: PMC7607000 DOI: 10.3389/fendo.2020.559674
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 5.555
Figure 1Impact of specific deletion of NTD from STARD1, in vivo, and of 1.8-kb in situ CRISPR STARD1 gene deletion in culture on cholesterol ester distribution. (A) Selective effects of NTD deletion on in vivo mitochondrial CHOL metabolism. (B) NTD deletion effects on LD accumulation match those for full STAR deletion. Sections A and B adapted from (10) (C) (i). Design for in situ CRISPR STARD1 deletion, which removes 1.8 kb of gene from RFP/GFP dual-marked cells. (ii and iii). After dual transfection (24 h), marked cells lose mRNA produced by 180-min of Br-cAMP stimulation. Compared to mean for adjacent unmarked cells (or g-RNA-null control cultures). (D) Effect after activation of 24-h CRISPR deletion of STARD1 in Y-1 cells (GFP Green) on neutral lipid accumulations ((+) gRNA; Quantified by cell fluorescence at 12, 24, and 48 h). (i). Oil red O (ORO) measured after 1-h stimulation by Br-cAMP following 24 h of CRISPR activation. Four adjacent cells: left pair, non-transfected; right pair, GFP+/transfected. (ii). Dot blot of ORO responses; Relative Integrated Optical Densities per individual cell (Int Dens/Cell). (E) Compare 1 h effects of Br-cAMP with deletion of STARD1 versus inhibition of CYP11A1 by AMG. ORO increases with AMG to similar extent as CRISPR deletion of STARD1, but in all cells. Right panels: Same cells stained for STARD1 in MITO at sites devoid of LD. AMG induces ORO-independent of STARD1 expression (Br-cAMP activation or CRISPR-deletion). Conclusion: AMG and STARD1 deletion produce similar effects by different mechanisms. Portions of C, D and E were adapted from (10).
Figure 2Five START proteins function in cholesterol trafficking between cell compartments and metabolism. START domain proteins function selectively in the movement of CHOL at select cell locations. STARD forms 1, 3, 4, 5 (ST 1, 3, 4, 5) complete specific inter-organelle CHOL transfer, as indicated. MTL (MENTAL) is a contact forming NTD for STARD3. GMD: GramD1B with has a central START and ER-specific C-terminal transmembrane domain. STARD proteins partner with oxysterol binding proteins. ORP1L and ORP5 each binds CHOL and HO-CHOL. Each function with extra targeting partners. Rab7 and VAP mediate MCS at LE/LY and ER, respectively. COMPONENTS OF TRAFFICKING. CHOL IMPORT: HDL, SR-B1, and GMD into ER. ACAT1 (Acyl-CoA Acyl transferase) converts CHOL to CHOL-Esters (CH-E) and mediates transfer to Lipid droplets (LD). HSL (hormone sensitive lipase) convert CH-E to CHOL for partnership with STARD1 (ST1). LDL receptors (LDLR) introduce ApoE/LDL into endosome network. LAL (lysosomal acidic lipase) releases CHOL. CHOL EXPORT: NPC1/NPC2 export CHOL from LE, mediated by ORP5. ABCA1 directs export to ApoA1 to form nascent HDL (nHDL). ABCG1 exports to HDL. CHOL SYNTHESIS: INSIG-SCAP-CHOL sensor suppresses until CHOL is very low. Then, SREBP, CHOL-dependent transcription factor, is cleaved in Golgi to activate 15 ER enzymes. CHOL RECYCLING through Autophagy: through LY-directed transfer to LE. CHOL STORAGE: as acyl esters in LD, via ER and ACAT1. CHOL MITO METABOLISM: limited by transfer from OMM to IMM, CYP11A1 produces pregnenolone. CYP27A1: produces HO-CHOL for LXRa pathways.
Figure 3STARD1 uses two Cholesterol Transfer Mechanisms: Roles of translation and NTD. (A) In a fluidic model of rat adrenal cell stimulation, corticosterone secretion is increased to a peak level by ACTH (A) in 10 min. This secretion is reversed by translation inhibitors puromycin (P) and anisomycin (An) within 10 min. Adapted from (61). (B) Measurement of pregnenolone (Preg) synthesis (ng/15 min/ml), in a 15-min window, following a 60-min Br-cAMP (cA)-stimulation of MA10 cells. HSD and CYP17 inhibitors, trilostane (5 uM) and abiraterone (10 uM) were added at the beginning of the 15-min synthesis window. This activation is only modestly inhibited by the addition of cycloheximide (CHX) in this 15 min window. *p<0.05; ***p<0.001. (C) (i). The NTD is comprised of alternate positively charged (yellow) and hydrophobic (purple) sequences cleaved to at conserved sites by mitochondrial metalloprotease, MPP, sequentially forming p35, p32 and p30 forms or directly cleave at site 54 to release p30 to the OMM. Denaturation of the START domain pushes against protein import, the matrix HSP70 and ATP/H+ pull the NTD into the matrix. p30 at the OMM and p32 with a hydrophobic NTD in the IMS can each move CHOL into the IMM, including from TSPO rafts. (ii). The inter-conversion of cleaved forms is shown. (iii). Conserved amphoteric mitochondrial recognition and hydrophobic p32 terminal sequences. (D) Two distinct mechanisms of CHOL transfer (green and brown) involving fast and slow translation/import steps. The fast process involves uncoupled transcription of 3.5-kb mRNA and a translation dependent CHOL transfer. The slow mechanism involves MAM ER mitochondria contacts, translation of 1.6-kb mRNA and association with HSP78.
Figure 4Role of mTORC1 in cholesterol trafficking and synthesis. Is there a link to STARD1 activity? The mTORC1 regulatory complex controls TOR1 kinase through multiple associated proteins. This activity is independently stimulated through LE/LY CHOL, which complexes with SLC38A9 (SLC38) and by amino acids (AA; Arg, Leu, Glu), each effecting association of mTORC1 with the lysosome surface. CHOL in LY/LE that forms the SLC38A9 complex derives from endocytosis of LDL/LDLR, delivered as CHOL-Esters. Lysosomal Acidic Lipase (LAL) releases free CHOL. CHOL is also delivered by lysosomes, including from autophagy recycling. NPC inhibits this activation directly and by CHOL depletion through export. mTORC1 is stimulated by insulin and growth factors that function through Akt and from diet via suppression by AMPK. mTORC1 is suppressed by ER stress processes (ATF6/PERK). TOR1 kinase activity increases CHOL synthesis, by lowering negative INSIG effects on SREBP2 activation by SCAP, when ER CHOL is low. TOR1 kinase suppresses autophagy and LY fusion to LE, but increases protein translation, via phosphorylation of ribosome S6K1 and initiation factor, 4E-BP. These effects on translation may extend to control of translation coupled STARD1 activity.
Figure 5Delayed splicing and asymmetric STARD1 expression at loci in MA10 cells. (A) Immediate increase in copy number for p-RNA at introns 1 and 6 reaches a steady state after 60 min of 30,000 copies (blue, right scale). Spliced transcripts (ORF) show delayed increases in sp-RNA (red, left scale). Primers measuring the extended UTR (brown, left scale) also show delay. (B) sm-FISH 40 oligomer sets for assessment of STARD1 p-RNA locus, sp-RNA/mRNA and extended 3’-EU of the 3.5-Kb mRNA. (C) Time course for asymmetric appearance of p-RNA (green, upper) and slower sp-RNA (red, lower) at STARD1 loci. (D) Stimulation of mRNA measured by sm-FISH (red) and accumulated STARD1 protein (antibody, green) in mitochondria. (E) sm-FISH detection of sp-RNA at loci and cytoplasmic mRNA at 0, 60, 75, 90, 120, and 180 min. Parts of this figure were previously published (145, 146).
Figure 7Special role of SIK and CRTC forms in the PKA stimulation of STARD1 RNA. (A) Slow splicing and alternative polyadenylation. Uncoupled generation of p-RNA is indicative of the delayed availability of splicing factors. Selective roles of TIS11b and AKAP1 on extended 3’UTR of 3.5-kb mRNA. 3.5-kb mRNA control translation and mRNA turnover at the mitochondria. There is probable differential targeting of MAM complexes by 1.6-kb form, which predominates later in MA10 cells. (B) SIK/CRTC control. PKA-mediated induction of STARD1 occurs via reversal of basal SIK/CRTC suppression. Two forms of SIK and CRTC are each maintained inactive through binding of phosphorylated forms by 14-3-3. They are activated by PP2 phosphatases. CRTC2 stimulates CREB when dephosphorylated. CRTC3 partners CRTC2 by enhancing PP2A phosphatase. Suppression of CRTC forms is delivered by basal SIK2 and inducible SIK1, which are, respectively, cytoplasmic and nuclear in their active dephosphorylated forms. (C) Pulsatile Control. An increase and decrease of cAMP and PKA over 20–30 min are produced by the normal pulse delivery of ACTH, in combination with cell PDE forms. SIK2 suppression mirrors this time course. SIK1 is induced in an inactive S577 phosphorylated form by high cAMP in the early phase, which then suppresses late in the pulse as cAMP falls. The delay in splicing and late SIK1 inhibition leads to low mRNA that persists between pulses. (D) Dual STARD1 activities. STARD1 is active in CHOL import and IMM metabolism at CYP11A1 (11A) when NTD cleaved form, p30, relocates to OMM. The additional activities of p30 STARD1 in IMS, IMM and matrix are poorly defined, particularly activities at CYP27A1 that lead to LXR activation.
Figure 6Y-1 cells show heterogeneous basal activation and acute, sustained loci activation with slow splicing and protein translation. (A) (i). Time course (qPCR copy number) for stimulation of STARD1 p-RNA (intron1 vs. intron6 (UPPER) and spRNA/mRNA (exon5/exon6; 3’UTR early (S) and extended (L) (LOWER). (ii). sm-FISH basal expression of same 5 cells probed with p-RNA and sp-RNA. The data demonstrate little relationship between p-RNA or sp-RNA at loci and mRNA in cytoplasm. (iii). p-RNA increases between 0 and 15 min but remain similar at 180 min. sp-RNA/mRNA at 180 min increase in a number of cells, with high expression in nucleus and cytoplasm. (B) Basal sp-RNA heterogeneity at high sensitivity captures both loci and mRNA. Varying proportions of locus activation and mRNA (a, b, c, d) may reflect different stages of a cycle comprising locus activation, mRNA processing, export, locus inactivation, mRNA turnover. (C) (i). Cytoplasmic mRNA particles counted from each of 30 adjacent cells (particle counts/cell) compared to protein expression (cell fluorescence): half the cells do not express detectable cytoplasmic mRNA. Delayed increase in cytoplasmic mRNA occurs from 60-180 min. ***p<.001; ns, not significantly different. (ii). Proportion of cells with high translated protein in mitochondria increases progressively 0–180 min. (D) (i). Total protein measured by immunoblot only increases after 15 min in Y-1 cells. (ii). Activity is fully increased in the first 15 min. MA10 activity increases only after 15 min and in parallel with increased protein accumulation. Portions of this figure were previously published (10, 145, 150).
Figure 8Activation of SIK1 and CRTC2; inhibition by SIK1S577A GFP. (A) SIK/CRTC responses in Y-1 cells. Inverse nuclear transfer of SIK1-GFP and CRTC2-GFP is stimulated with Br-cAMP. (B) Stimulation of SIK1 pRNA and 10.7554/eLife.25466 mRNA (total and extended 4.4-kb forms). (C) Stimulation of STARD1 by inhibition of SIK forms. (i). Inhibition with 30 nM staurosporine (ST) compared to Br-cAMP (cA, 0.4 uM) (p-RNA/pre-mRNA and sp-RNA/mRNA). (ii). sm-FISH images of STARD1 p-RNA and sp-RNA at loci after 180 min with 30 nM ST. (D) Inhibition of CRTC by transfection with SIK1-S577A-GFP. (i). Inhibition of STARD1 mRNA in Y-1 cells, but not in adjacent non-transfected cells. (ii). Expression comparison of STARD1 mRNA particles in 26 adjacent cells from the same culture, with (S577A) and without (WT) transfection. Portions of this figure were previously published (145, 150, 164). ***p<0.001.
Figure 9Expression of STARD1 3.5- and 1.6-kb mRNA. Selective targeting of TIS11b to 3.5 kb form. (A). (i). In MA10 cells, Br-cAMP stimulates the 3.5-kb form for 3 h, followed by a decline. The 1.6-kb form is constant. (ii). Diagram of STARD1 3’UTR sites on 1.6 and 3.5-kb mRNA. (iii). The extended 3’UTR retains two or three 8-base TIS11b binding sites in mouse and bovine sequences. (iv). Domain structure of TIS11b. (B) (i). Y-1 and MA10 cells both show Br-cAMP-mediated increases in TIS11b expression. (ii). Co-expression of STARD1 forms with different 3’UTR. TIS11b selectively suppresses 3.5-kb form and STARD1 protein. (C) In MA10 cells, impact of supplemental transfection of dUTR STARD1 on S195 phosphorylation, NTD cleavage and pregnenolone formation. Early CHOL metabolism is increased, but not 30- and 60-min stimulations. The p37/p30 ratio is much higher for phospho-STARD1. (D) (i). sm-FISH analysis in Y-1 cells shows overlap (yellow) of ORF/sp-RNA (red) and extended 3’UTR/3’EU (green) at the loci after stimulation for 120 min. (ii). sp-RNA/ORF and 3’UTR/3’EU probes each bind 3.5-kb mRNA. Seventy percent (see inserts) of mRNA show 3’EU (green), half paired with sp-RNA/ORF (red). Thirty percent only bind sp-RNA/ORF (red). Portions of this figure were previously published (150, 164).
Figure 10sm-FISH identification of single cell location of STARD1 mRNA in relation to gene loci and mitochondria. Identification of 1:1 mRNA-mitochondria association. (A) MA10 cell 3D assembly of STARD1 sp-RNA/mRNA and protein/mitochondria 180 min after Br-cAMP stimulation. (i). XY shows top view; (ii). XZ shows side view. (A–C) arrows indicate levels used for three optical slices in B. Red: sp-RNA at loci (intense) and in cytosol as mRNA; Green: STARD1 protein in mitochondrial matrix. Studies with Mitotracker and STARD1 protein show near total overlap. (B) In slices A and B, mitochondria with high STARD1 protein (green/white) mark the nuclear envelope, which they encircle. Same two nuclei (red/white; arrows) are detected in each section (slice A>slice B). Single mRNA particles (red) move from loci to nuclear pores. Outside the nucleus, many mRNA pair with single mitochondria marked by STARD1 protein (boxed area enlarged in section C). Slice C is below the nucleus. mRNA less frequently paired with mitochondria (see section A). (C) (i). Diagram shows spacing for mRNA attached to ribosome, separated from STARD1 protein in the mitochondrion matrix. (iii). Pairing of mRNA and mitochondria (box slice B). (D) Diagram shows movement of mRNA particles from loci to lower cytoplasm zone. (E) Y-1 cells imaged for STARD1 sp-RNA/mRNA and protein/mitochondria. (i). 3 basal cells (A, B, C) marked by DAP1 nuclei each show STARD1 mRNA (red) and protein (green). (Box Enlarged) Cell C; 15-20 mRNA particles and mitochondria/STARD1 with six examples of mRNA/mitochondrion pairs. (ii). 15-min Br-cAMP stimulation (four cells). Similar pairing of mRNA and mitochondria. Some mitochondria cluster without mRNA. Portions of this figure were previously published (146, 150).
Figure 11sm-FISH facilitates visualization of STARD1 and Cyp11a1 primary and spliced transcripts at the resolution of single Leydig cells after hCG injection of adult male mice. (A) Immunohistochemistry of 3b-HSD protein (unaffected by hCG). Left: Standard 100x image of a single interstitial zone; Right: 3D deconvolution. (B) Two Leydig cells after 240-min stimulation of STARD1 mRNA (red) resolved by NSIM. Cells are bordered by EGFP that locates to the plasma membrane of Leydig Cells in Cyp11a1Cre+;mTmG mice. A single locus is expressing p-RNA (green in nucleus). (C) sm-FISH analysis of STARD1 loci for duplicate sections (p-RNA, green; sp-RNA, red; overlap, yellow) at 0-, 60-, and 240-min post hCG stimulation. 0 min: 1 p-RNA/9 cells; 60 min: 10/11 cells with loci (many with dual p-RNA/sp-RNA presence-yellow); 240-min variable loci express RNA in parallel with mRNA (low sensitivity). Columns a and b represent different populations of cells within the same section of the testis. (D) Images of interstitial cells following 240-min hCG stimulation, 3D de-convolution for Cyp11a1 and STARD1 (high sensitivity). Cyp11a1 shows similar expression at basal and induced conditions (not shown). STARD1 shows similar induced mRNA levels but with different positioning. Portions of this figure were previously published (182).
Cell type dependence of STARD1 mechanism.
| Characteristic | Y-1 Adrenal | MA10 Testis | |
|---|---|---|---|
| Early Uncoupled Splicing | Yes | Yes | Yes |
| Sustained slow splicing | Yes | Yes | |
| Delayed mRNA increase | YES | YES | YES |
| 3.5kb mRNA dominant | YES | YES | YES |
| Basal pRNA, spRNA, mRNA | YES | NO | |
| Asymmetric Locus Activation | YES | YES | YES |
| Paired mRNA-Mitochondria | YES | YES | ? |
| Deletion activated LD | YES | YES | YES |
| CRTC2 SIK S577A inhibit | YES | YES | ? |
| Stimulation by SIK Inhibitor | YES | YES | ? |
| High SIK1 induction | YES | YES | ? |
| Acute Translation-Coupled CHOL Metabolism | YES | ? | ? |
| Delayed ER-MAM Complex | ? | YES | ? |
See for graphic representation; – for data.